Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma.

Grasso S, Cangelosi D, Chapelle J, Alzona M, Centonze G, Lamolinara A, Salemme V, Angelini C, Morellato A, Saglietto A, Bianchi FT, Cabodi S, Salaroglio IC, Fusella F, Ognibene M, Iezzi M, Pezzolo A, Poli V, Di Cunto F, Eva A, Riganti C, Varesio L, Turco E, Defilippi P.

Cell Death Differ. 2019 Jul 8. doi: 10.1038/s41418-019-0386-6. [Epub ahead of print]

PMID:
31285546
2.

NEOTROPICAL XENARTHRANS: a data set of occurrence of xenarthran species in the Neotropics.

Santos PM, Bocchiglieri A, Chiarello AG, Paglia AP, Moreira A, de Souza AC, Abba AM, Paviolo A, Gatica A, Medeiro AZ, Costa AN, Gallina AG, Yanosky AA, Jesus A, Bertassoni A, Rocha A, Bovo AAA, Bager A, Mol AC, Martensen AC, Faustino AC, Lopes AMC, Percequillo AR, Vogliotti A, Keuroghlian A, de la Colina MA, Devlin AL, García-Olaechea A, Sánchez A, Srbek-Araujo AC, Ochoa AC, Oliveira ACM, Lacerda ACR, Campelo AKN, de Oliveira Paschoal AM, Costa ARC, Meiga AYY, Jesus AS, Feijó A, Hirsch A, da Silva ALF, Botelho ALM, Regolin AL, Lanna AM, Nunes AV, Kindel A, Moraes AM, Gatti A, Noss AJ, Nobre AB, Montanarin A, Deffaci ÂC, de Albuquerque ACF, de Oliveira AK, Mangione AM, Pontes ARM, Bertoldi AT, Calouro AM, Desbiez ALJ, Fernandes A, Ferreguetti AC, da Silva MAA, Zimbres B, Luciano BFL, de Thoisy B, Niebuhr BBS, Papi B, Gómez-Valencia B, Santos BA, Lima BC, Oliveira BG, Santos BS, Campos BATP, Leles B, de Albuquerque França BR, Lim B, Oliveira CT, Cantagallo C, Lara CC, Lima CS, Gestich CC, de Melo-Soares CD, Peres CA, Kasper CB, Candia-Gallardo C, De Angelo C, Fragoso CE, de Freitas CH, Salvador CH, Brocardo CR, Melo CD, Leuchtenberger C, Braga C, Sánchez-Lalinde C, Bueno C, Luna CL, Rojano C, Hurtado CM, Dos Santos CC, Tellaeche C, Rosa C, de Campos CB, Silva CR, Kanda CZ, Jenkins CN, McDonough C, Trinca CT, da Cunha CJ, Widmer CE, Santos C, Buscariol D, Carreira DC, Carvalho DR, da Silva Ferraz D, Casali D, Thornton D, Vasconcellos DR, Barcelos D, Brown D, Ramos DL, Moreira DO, Yogui DR, Faria D, Sana DA, de Mattia DL, Henz DJ, Friedeberg DB, Carvalho DLKP, Astúa D, Queirolo D, Varela DM, Eaton DP, Dias DM, Rivadeneira EF, Rocha EC, de Abreu-Júnior EF, Carrano E, Santos EM Jr, Setz EZF, Carvalho EAR Jr, de Almeida Chiquito E, de Matos Cardoso E, Mendonça EN, D'Bastiani E, Vieira EM, Ramalho EE, Guijosa-Guadarrama E, González E, Maggiorini EV, Fischer E, Aguiar EF, Castro ÉP, de la Peña-Cuéllar E, de Castro EBV, Brítez EB, Vanderhoeven EA, Pedó E, Rocha FL, Girardi F, de Oliveira Roque F, Mazim FD, de Barros FM, Martello F, Fantacini FM, Pedrosa F, Peters FB, Abra FD, de Azevedo FC, da Silva Santos F, da Silva FG, Teixeira FZ, Perini FA, Passos FC, Carvalho F, de Azevedo FCC, de Pinho FF, Gonçalves F, Lima F, Contreras-Moreno FM, Pedroni F, Tortato FR, Santos FPR, Caruso F, Tirelli FP, Miranda FR, Rodrigues FHG, Ubaid FK, Palmeira FBL, da Silva FA, Grotta-Neto F, de Souza FL, Costa FE, Pérez-Garduza F, Delsuc F, Lemos F, Pinto FR, Boaglio GI, Massocato GF, Preuss G, Hofmann GS, Aguiar GL, Oliveira GS, Duarte GT, Beca G, Giné GAF, Batista GO, Gil GE, Gonsioroski G, Secco H, Medeiros HR, Coelho IP, Franceschi IC, Bernardi I, de la Torre JA, Zocche JJ, Seibert JB, de Faria Falcão JC, Dias JHM, Nodari JZ, Oliveira JA, Giovanelli JGR, Favoretti JPP, Polisar J, Sponchiado J, Cherem JJ, Ramírez JFM, de Toledo JJ, Duarte JMB, de Matos JR, Arrabal JP, de Faria Oshima JE, Ribeiro JF, Bogoni JA, Pacheco JJC, Schuchmann KL, Ferraz KMPMB, Dos Santos Everton L, Bailey LL, Gonçalves LO, Cullen L Jr, de Andrade LR, Trevelin LC, Bonjorne L, de Almeida Rodrigues L, Leuzinger L, Perillo LN, Araújo LS, Hufnagel L, Ribeiro LO, Bernardo LRR, Oliveira-Santos LGR, Varzinczak LH, Borges LHM, Guimarães LN, Möcklinghoff L, Oliveira MA, Magioli M, de Assis Jardim MM, de Oliveira ML, Tortato MA, Dums M, Iezzi ME, Pereira MJR, Jorge ML, de Castro Morini MS, Landis MB, Xavier MS, Barros MAS, da Silva ML, Rivero M, Zanin M, Marques MI, Alves MH, Di Bitetti MS, Alvarez MR, Graipel ME, Godoi MN, Benedetti MA, Beltrão MG, Monteiro MCM, de Paula MJ, Perilli MLL, da Silva MP, Villar N, De Albuquerque NM, Canassa NF, Filho NM, da Rosa Oliveira N, Pasqualotto N, Cáceres NC, Attias N, Favarini MO, Ribeiro OS, Gonçalves PR, da Rocha PA, Condé PA, Akkawi P, Cruz P, Lira PK, Ferreira PM, Arroyo-Gerala P, Hartmann PA, de Tarso Zuquim Antas P, Marinho PH, de Faria Peres PH, Peña-Mondragón JL, Lombardi PM, de Souza Laurindo R, Alves RSC, Grangeiro RDP, Silva RL, Beltrão-Mendes R, Bonikowski RTR, Reppucci J, Arrais RC, Sampaio R, Sartorello R, Bovendorp RS, McNab R, Hack ROE, Magalhães RA, Araújo RC, de Almeida Nobre R, Pérez RRL, Massara RL, de Paula RC, Anleu RG, Marques RV, Dornas R, Rolim SG, Cavalcanti SMC, Lima SR, Ballari SA, Santamaría SB, Silva SM, Age SG, Godim T, Sobral-Souza T, Maccarini TB, Rodrigues TF, Piovezan U, Tavares VDC, Quiroga VA, Krepschi VG, Filho VP, Bastazini VAG, de Oliveira Gasparotto VP, Orsini VS, Layme VMG, Hannibal W, Dáttilo W, de Carvalho WD, Loughry WJ, Di Blanco YE, Núñez-Regueiro MM, Giubbina MF, Passamani M, de Alagão Querido LC, da Costa Toledo GA, Ribeiro IK, Quintilham L, de Bustos S, de la Maza J, Neto JFL, de Andrade Silva KVK, Sartorello L, Rampim LE, Marás GA, Camino M, Freitas-Junior M, Perovic PG, Paolino RM, Ferreira SD, Towns V, Esperandio IB, Aximoff I, Beduschi J, Guenther M, de Cassia Bianchi R, Keuroghlian-Eaton S, Mendes SL, de Fatima Cunha L, Cirignoli S, Ciocheti G, do Prado HA, Fernandes-Ferreira H, de Sena LMM, Yamane MH, Brennand PGG, da Silva RD, Escobar S, Endo W, Hurtado RR, Gontijo NRC, Marsh LK, Severo MM, Pardo JM, Costa SA, Melo GL, Santana GG, de Miranda Mourão G, Gaspari GG, Duarte H, Cabral H, da Silva LH, Mendonça L, Barbosa LL, Dos Santos MV, Moraes MFD, Gordo M, Versiani NF, Cantero N, Pays O, Guedes PG, Colas-Rosas PF, Ribeiro P, Renaud PC, Hoogesteijn RJ, Ayala R, da Cunha RGT, Schaub R, Laurito S, Betkowski SE, Cortez S, Silva SSP, de Oliveira TG, Spironello WR, Gengler N, Hidalgo MM, Juárez R, Iglesias JA, Anacleto TC, de Souza Fialho M, Cavicchioli G, Beccato MAB, Silva MD, Neto OC, Lopes KGD, Godoy LP, Luiz MR, Rojas Bonzi VB, Ferreira GB, Oliveira MJR, Hinojosa J, de Oliveira LFB, Nagy-Reis MB, Ramirez SF, Concone HVB, Mourthe I, Martínez-Lanfranco JA, Zanoni JB, Moreira TC, Guarderas ZV, Bazilio S, Cervini M, Pinheiro MS, Morato RG, Peroni N, Trigo TC, Machado RB, Gaspari F, Koenemann JG, Rudolf JC, Benchimol M, Vieira MV, Retta LM, Santiago PGF, Ciccia PG, Estrela PC, Carvalho S, Esbérard CEL, de la Cruz YB, Castro-Prieto J, Braga RM, Cartes JL, Andrade-Núñez MJ, Denkiewicz NM, Falconi N, Pezzuti JCB, Del Castillo Cordero HF, de Sousa LC, de Gaspari Júnior RL, Santos-Filho M, Almeida JS, Thompson JJ, Dos Santos JS, Pereira-Ribeiro J, Burs K, da Silva KFM, Velilla M, da Silva MX, de la Sancha NU, Pinheiro PF, de Castilho PV, Bercê W, Assis JC, Tonetti VR, Alves-Eigenheer M, Chinem S, Honda LK, de Godoy Bergallo H, Alberici V, Wallace R, Krauer JMC, Ribeiro MC, Galetti M.

Ecology. 2019 Jul;100(7):e02663. doi: 10.1002/ecy.2663. Epub 2019 Apr 23.

PMID:
31013542
3.

Pharmacokinetic considerations for anti-epileptic drugs in children.

Verrotti A, Iapadre G, Di Donato G, Di Francesco L, Zagaroli L, Matricardi S, Belcastro V, Iezzi ML.

Expert Opin Drug Metab Toxicol. 2019 Mar;15(3):199-211. doi: 10.1080/17425255.2019.1575361. Epub 2019 Feb 7. Review.

PMID:
30689454
4.

Induction of immunosuppressive functions and NF-κB by FLIP in monocytes.

Fiore A, Ugel S, De Sanctis F, Sandri S, Fracasso G, Trovato R, Sartoris S, Solito S, Mandruzzato S, Vascotto F, Hippen KL, Mondanelli G, Grohmann U, Piro G, Carbone C, Melisi D, Lawlor RT, Scarpa A, Lamolinara A, Iezzi M, Fassan M, Bicciato S, Blazar BR, Sahin U, Murray PJ, Bronte V.

Nat Commun. 2018 Dec 5;9(1):5193. doi: 10.1038/s41467-018-07654-4.

5.

Investigational small molecules in phase II clinical trials for the treatment of epilepsy.

Greco M, Varriale G, Coppola G, Operto F, Verrotti A, Iezzi ML.

Expert Opin Investig Drugs. 2018 Dec;27(12):971-979. doi: 10.1080/13543784.2018.1543398. Epub 2018 Nov 13. Review.

PMID:
30408428
6.

Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer.

Bartolacci C, Andreani C, Curcio C, Occhipinti S, Massaccesi L, Giovarelli M, Galeazzi R, Iezzi M, Tilio M, Gambini V, Wang J, Marchini C, Amici A.

Cancer Immunol Res. 2018 Dec;6(12):1486-1498. doi: 10.1158/2326-6066.CIR-18-0179. Epub 2018 Oct 16. Erratum in: Cancer Immunol Res. 2019 Mar;7(3):526.

PMID:
30327365
7.

Effects of human impacts on habitat use, activity patterns and ecological relationships among medium and small felids of the Atlantic Forest.

Cruz P, Iezzi ME, De Angelo C, Varela D, Di Bitetti MS, Paviolo A.

PLoS One. 2018 Aug 1;13(8):e0200806. doi: 10.1371/journal.pone.0200806. eCollection 2018.

8.

MiR-205-5p inhibition by locked nucleic acids impairs metastatic potential of breast cancer cells.

De Cola A, Lamolinara A, Lanuti P, Rossi C, Iezzi M, Marchisio M, Todaro M, De Laurenzi V.

Cell Death Dis. 2018 Jul 26;9(8):821. doi: 10.1038/s41419-018-0854-9.

9.

Generation of multiparametric MRI maps by using Gd-labelled- RBCs reveals phenotypes and stages of murine prostate cancer.

Ferrauto G, Di Gregorio E, Lanzardo S, Ciolli L, Iezzi M, Aime S.

Sci Rep. 2018 Jul 12;8(1):10567. doi: 10.1038/s41598-018-28926-5.

10.

In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer.

Gambini V, Tilio M, Maina EW, Andreani C, Bartolacci C, Wang J, Iezzi M, Ferraro S, Ramadori AT, Simon OC, Pucciarelli S, Wu G, Dou QP, Marchini C, Galassi R, Amici A.

Eur J Med Chem. 2018 Jul 15;155:418-427. doi: 10.1016/j.ejmech.2018.06.002. Epub 2018 Jun 2.

PMID:
29906688
11.

Clitoromegaly in Childhood and Adolescence: Behind One Clinical Sign, a Clinical Sea.

Iezzi ML, Lasorella S, Varriale G, Zagaroli L, Ambrosi M, Verrotti A.

Sex Dev. 2018;12(4):163-174. doi: 10.1159/000489385. Epub 2018 May 26. Review.

12.

Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.

Castiello L, Sestili P, Schiavoni G, Dattilo R, Monque DM, Ciaffoni F, Iezzi M, Lamolinara A, Sistigu A, Moschella F, Pacca AM, Macchia D, Ferrantini M, Zeuner A, Biffoni M, Proietti E, Belardelli F, Aricò E.

Cancer Immunol Res. 2018 Jun;6(6):658-670. doi: 10.1158/2326-6066.CIR-17-0675. Epub 2018 Apr 5.

13.

Author Correction: The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries.

Grasso S, Chapelle J, Salemme V, Aramu S, Russo I, Vitale N, di Cantogno LV, Dallaglio K, Castellano I, Amici A, Centonze G, Sharma N, Lunardi S, Cabodi S, Cavallo F, Lamolinara A, Stramucci L, Moiso E, Provero P, Albini A, Sapino A, Staaf J, Di Fiore PP, Bertalot G, Pece S, Tosoni D, Confalonieri S, Iezzi M, Di Stefano P, Turco E, Defilippi P.

Nat Commun. 2018 Mar 30;9:16203. doi: 10.1038/ncomms16203.

14.

EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma.

Capone E, Lamolinara A, D'Agostino D, Rossi C, De Laurenzi V, Iezzi M, Iacobelli S, Sala G.

J Control Release. 2018 May 10;277:48-56. doi: 10.1016/j.jconrel.2018.03.016. Epub 2018 Mar 14.

15.

Single-Domain Antibodies and the Promise of Modular Targeting in Cancer Imaging and Treatment.

Iezzi ME, Policastro L, Werbajh S, Podhajcer O, Canziani GA.

Front Immunol. 2018 Feb 19;9:273. doi: 10.3389/fimmu.2018.00273. eCollection 2018. Review.

16.

EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma.

Capone E, Giansanti F, Ponziani S, Lamolinara A, Iezzi M, Cimini A, Angelucci F, Sorda R, Laurenzi V, Natali PG, Ippoliti R, Iacobelli S, Sala G.

Oncotarget. 2017 Sep 8;8(56):95412-95424. doi: 10.18632/oncotarget.20728. eCollection 2017 Nov 10.

17.

Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy.

Sandri S, De Sanctis F, Lamolinara A, Boschi F, Poffe O, Trovato R, Fiore A, Sartori S, Sbarbati A, Bondanza A, Cesaro S, Krampera M, Scupoli MT, Nishimura MI, Iezzi M, Sartoris S, Bronte V, Ugel S.

Oncotarget. 2017 May 23;8(50):86987-87001. doi: 10.18632/oncotarget.18115. eCollection 2017 Oct 20.

18.

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

Palladini A, Nicoletti G, Lamolinara A, Dall'Ora M, Balboni T, Ianzano ML, Laranga R, Landuzzi L, Giusti V, Ceccarelli C, Santini D, Taffurelli M, Di Oto E, Asioli S, Amici A, Pupa SM, De Giovanni C, Tagliabue E, Iezzi M, Nanni P, Lollini PL.

Oncotarget. 2017 Apr 13;8(33):54444-54458. doi: 10.18632/oncotarget.17088. eCollection 2017 Aug 15.

19.

ATLANTIC-CAMTRAPS: a dataset of medium and large terrestrial mammal communities in the Atlantic Forest of South America.

Lima F, Beca G, Muylaert RL, Jenkins CN, Perilli MLL, Paschoal AMO, Massara RL, Paglia AP, Chiarello AG, Graipel ME, Cherem JJ, Regolin AL, Oliveira Santos LGR, Brocardo CR, Paviolo A, Di Bitetti MS, Scoss LM, Rocha FL, Fusco-Costa R, Rosa CA, Da Silva MX, Hufnagell L, Santos PM, Duarte GT, Guimarães LN, Bailey LL, Rodrigues FHG, Cunha HM, Fantacini FM, Batista GO, Bogoni JA, Tortato MA, Luiz MR, Peroni N, De Castilho PV, Maccarini TB, Filho VP, Angelo C, Cruz P, Quiroga V, Iezzi ME, Varela D, Cavalcanti SMC, Martensen AC, Maggiorini EV, Keesen FF, Nunes AV, Lessa GM, Cordeiro-Estrela P, Beltrão MG, De Albuquerque ACF, Ingberman B, Cassano CR, Junior LC, Ribeiro MC, Galetti M.

Ecology. 2017 Nov;98(11):2979. doi: 10.1002/ecy.1998.

PMID:
28857166
20.

Resveratrol has anti-thyroid effects both in vitro and in vivo.

Giuliani C, Iezzi M, Ciolli L, Hysi A, Bucci I, Di Santo S, Rossi C, Zucchelli M, Napolitano G.

Food Chem Toxicol. 2017 Sep;107(Pt A):237-247. doi: 10.1016/j.fct.2017.06.044. Epub 2017 Jun 28.

PMID:
28668442
21.

Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection.

Codagnone M, Cianci E, Lamolinara A, Mari VC, Nespoli A, Isopi E, Mattoscio D, Arita M, Bragonzi A, Iezzi M, Romano M, Recchiuti A.

Mucosal Immunol. 2018 Jan;11(1):35-49. doi: 10.1038/mi.2017.36. Epub 2017 Apr 19.

PMID:
28422188
22.

The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries.

Grasso S, Chapelle J, Salemme V, Aramu S, Russo I, Vitale N, Verdun di Cantogno L, Dallaglio K, Castellano I, Amici A, Centonze G, Sharma N, Lunardi S, Cabodi S, Cavallo F, Lamolinara A, Stramucci L, Moiso E, Provero P, Albini A, Sapino A, Staaf J, Di Fiore PP, Bertalot G, Pece S, Tosoni D, Confalonieri S, Iezzi M, Di Stefano P, Turco E, Defilippi P.

Nat Commun. 2017 Mar 16;8:14797. doi: 10.1038/ncomms14797. Erratum in: Nat Commun. 2018 Mar 30;9:16203.

23.

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor.

Andreani C, Bartolacci C, Wijnant K, Crinelli R, Bianchi M, Magnani M, Hysi A, Iezzi M, Amici A, Marchini C.

Aging (Albany NY). 2017 Feb 26;9(2):508-523. doi: 10.18632/aging.101175.

24.

The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.

Bandini S, Macagno M, Hysi A, Lanzardo S, Conti L, Bello A, Riccardo F, Ruiu R, Merighi IF, Forni G, Iezzi M, Quaglino E, Cavallo F.

Oncoimmunology. 2016 Nov 8;5(12):e1253653. doi: 10.1080/2162402X.2016.1253653. eCollection 2016.

25.

Stories of experiences of care for growth hormone deficiency: the CRESCERE project.

Marini MG, Chesi P, Mazzanti L, Guazzarotti L, Toni TD, Salerno MC, Officioso A, Parpagnoli M, Angeletti C, Faienza MF, Iezzi ML, Aversa T, Sacchetti C.

Future Sci OA. 2016 Feb 25;2(1):FSO82. doi: 10.4155/fso.15.82. eCollection 2016 Mar.

26.

Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.

Corda G, Sala G, Lattanzio R, Iezzi M, Sallese M, Fragassi G, Lamolinara A, Mirza H, Barcaroli D, Ermler S, Silva E, Yasaei H, Newbold RF, Vagnarelli P, Mottolese M, Natali PG, Perracchio L, Quist J, Grigoriadis A, Marra P, Tutt AN, Piantelli M, Iacobelli S, De Laurenzi V, Sala A.

J Pathol. 2017 Feb;241(3):350-361. doi: 10.1002/path.4841. Epub 2016 Dec 29.

27.

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer.

Castagnoli L, Ghedini GC, Koschorke A, Triulzi T, Dugo M, Gasparini P, Casalini P, Palladini A, Iezzi M, Lamolinara A, Lollini PL, Nanni P, Chiodoni C, Tagliabue E, Pupa SM.

Oncogene. 2017 Mar 23;36(12):1721-1732. doi: 10.1038/onc.2016.338. Epub 2016 Sep 19.

28.

Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.

Carrella D, Manni I, Tumaini B, Dattilo R, Papaccio F, Mutarelli M, Sirci F, Amoreo CA, Mottolese M, Iezzi M, Ciolli L, Aria V, Bosotti R, Isacchi A, Loreni F, Bardelli A, Avvedimento VE, di Bernardo D, Cardone L.

Oncotarget. 2016 Sep 13;7(37):58743-58758. doi: 10.18632/oncotarget.11318.

29.

Irreversible inhibition of Δ16HER2 is necessary to suppress Δ16HER2-positive breast carcinomas resistant to Lapatinib.

Tilio M, Gambini V, Wang J, Garulli C, Kalogris C, Andreani C, Bartolacci C, Elexpuru Zabaleta M, Pietrella L, Hysi A, Iezzi M, Belletti B, Orlando F, Provinciali M, Galeazzi R, Marchini C, Amici A.

Cancer Lett. 2016 Oct 10;381(1):76-84. doi: 10.1016/j.canlet.2016.07.028. Epub 2016 Jul 27.

PMID:
27475932
30.

Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies.

Sandri S, Bobisse S, Moxley K, Lamolinara A, De Sanctis F, Boschi F, Sbarbati A, Fracasso G, Ferrarini G, Hendriks RW, Cavallini C, Scupoli MT, Sartoris S, Iezzi M, Nishimura MI, Bronte V, Ugel S.

Cancer Res. 2016 May 1;76(9):2540-51. doi: 10.1158/0008-5472.CAN-15-2318.

31.

A unique case of growth hormone and human chorionic gonadotropin treatment in a 45,X male with Y: autosome translocation and literature review.

Mareri A, Iezzi M, Salvatore A, Ligas C, D'Alessandro E.

J Pediatr Endocrinol Metab. 2016 Jul 1;29(7):857-62. doi: 10.1515/jpem-2015-0427. Review.

PMID:
27054600
32.

The water soluble ruthenium(II) organometallic compound [Ru(p-cymene)(bis(3,5 dimethylpyrazol-1-yl)methane)Cl]Cl suppresses triple negative breast cancer growth by inhibiting tumor infiltration of regulatory T cells.

Montani M, Pazmay GVB, Hysi A, Lupidi G, Pettinari R, Gambini V, Tilio M, Marchetti F, Pettinari C, Ferraro S, Iezzi M, Marchini C, Amici A.

Pharmacol Res. 2016 May;107:282-290. doi: 10.1016/j.phrs.2016.03.032. Epub 2016 Mar 30.

PMID:
27038531
33.

Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.

Chikh A, Ferro R, Abbott JJ, Piñeiro R, Buus R, Iezzi M, Ricci F, Bergamaschi D, Ostano P, Chiorino G, Lattanzio R, Broggini M, Piantelli M, Maffucci T, Falasca M.

Oncotarget. 2016 Apr 5;7(14):18325-45. doi: 10.18632/oncotarget.7761.

34.

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.

Marchetti A, Di Lorito A, Pace MV, Iezzi M, Felicioni L, D'Antuono T, Filice G, Guetti L, Mucilli F, Buttitta F.

J Thorac Oncol. 2016 Apr;11(4):487-95. doi: 10.1016/j.jtho.2015.12.111. Epub 2016 Feb 22.

35.

Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.

Lamolinara A, Stramucci L, Hysi A, Iezzi M, Marchini C, Mariotti M, Amici A, Curcio C.

J Immunol Res. 2015;2015:159145. doi: 10.1155/2015/159145. Epub 2015 Jul 13.

36.

Antitumor immunization of mothers delays tumor development in cancer-prone offspring.

Barutello G, Curcio C, Spadaro M, Arigoni M, Trovato R, Bolli E, Zheng Y, Ria F, Quaglino E, Iezzi M, Riccardo F, Holmgren L, Forni G, Cavallo F.

Oncoimmunology. 2015 Feb 3;4(5):e1005500. eCollection 2015 May.

37.

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Croci S, Nanni P, Palladini A, Nicoletti G, Grosso V, Benegiamo G, Landuzzi L, Lamolinara A, Ianzano ML, Ranieri D, Dall'Ora M, Iezzi M, De Giovanni C, Lollini PL.

Breast Cancer Res. 2015 May 22;17:70. doi: 10.1186/s13058-015-0588-x.

38.

Claudin-4 SPECT Imaging Allows Detection of Aplastic Lesions in a Mouse Model of Breast Cancer.

Mosley M, Knight J, Neesse A, Michl P, Iezzi M, Kersemans V, Cornelissen B.

J Nucl Med. 2015 May;56(5):745-51. doi: 10.2967/jnumed.114.152496. Epub 2015 Apr 3.

39.

Effect of maternal exposure to endocrine disrupting chemicals on reproduction and mammary gland development in female Sprague-Dawley rats.

Manservisi F, Gopalakrishnan K, Tibaldi E, Hysi A, Iezzi M, Lambertini L, Teitelbaum S, Chen J, Belpoggi F.

Reprod Toxicol. 2015 Jul;54:110-9. doi: 10.1016/j.reprotox.2014.12.013. Epub 2014 Dec 29.

40.

Imaging DNA damage allows detection of preneoplasia in the BALB-neuT model of breast cancer.

Cornelissen B, Able S, Kartsonaki C, Kersemans V, Allen PD, Cavallo F, Cazier JB, Iezzi M, Knight J, Muschel R, Smart S, Vallis KA.

J Nucl Med. 2014 Dec;55(12):2026-31. doi: 10.2967/jnumed.114.142083. Epub 2014 Nov 13.

41.

Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.

Castagnoli L, Iezzi M, Ghedini GC, Ciravolo V, Marzano G, Lamolinara A, Zappasodi R, Gasparini P, Campiglio M, Amici A, Chiodoni C, Palladini A, Lollini PL, Triulzi T, Menard S, Nanni P, Tagliabue E, Pupa SM.

Cancer Res. 2014 Nov 1;74(21):6248-59. doi: 10.1158/0008-5472.CAN-14-0983. Epub 2014 Aug 27.

42.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

Chiari R, Buttitta F, Iacono D, Bennati C, Metro G, Di Lorito A, Iezzi M, Tiseo M, Mazzoni F, Cappuzzo F, Marchetti A, Crinò L.

Clin Lung Cancer. 2014 Nov;15(6):470-4. doi: 10.1016/j.cllc.2014.06.004. Epub 2014 Jun 24. No abstract available.

PMID:
25087901
43.

Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.

Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, Carrara M, Fiore A, Nuzzo S, Bicciato S, Nanni P, Landuzzi L, Cavallo F, Calogero R, Quaglino E.

BMC Genomics. 2014;15 Suppl 3:S1. doi: 10.1186/1471-2164-15-S3-S1. Epub 2014 May 6.

44.

Sanguinarine suppresses basal-like breast cancer growth through dihydrofolate reductase inhibition.

Kalogris C, Garulli C, Pietrella L, Gambini V, Pucciarelli S, Lucci C, Tilio M, Zabaleta ME, Bartolacci C, Andreani C, Giangrossi M, Iezzi M, Belletti B, Marchini C, Amici A.

Biochem Pharmacol. 2014 Aug 1;90(3):226-34. doi: 10.1016/j.bcp.2014.05.014. Epub 2014 May 27.

PMID:
24875448
45.

Multiple roles of perforin in hampering ERBB-2 (Her-2/neu) carcinogenesis in transgenic male mice.

Macagno M, Bandini S, Stramucci L, Quaglino E, Conti L, Balmas E, Smyth MJ, Lollini PL, Musiani P, Forni G, Iezzi M, Cavallo F.

J Immunol. 2014 Jun 1;192(11):5434-41. doi: 10.4049/jimmunol.1301248. Epub 2014 Apr 30.

46.

rBet v 1 immunotherapy of sensitized mice with Streptococcus thermophilus as vehicle and adjuvant.

Petrarca C, Clemente E, Toto V, Iezzi M, Rossi C, Zanotta S, Mistrello G, Zanoni I, Granucci F, Arioli S, Mora D, Guglielmetti S, Paganelli R, Di Gioacchino M.

Hum Vaccin Immunother. 2014;10(5):1228-37. doi: 10.4161/hv.28155. Epub 2014 Mar 6.

47.

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.

De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Ianzano ML, Dall'Ora M, Grosso V, Ranieri D, Laranga R, Croci S, Amici A, Penichet ML, Iezzi M, Cavallo F, Nanni P, Lollini PL.

Breast Cancer Res. 2014 Jan 23;16(1):R10. doi: 10.1186/bcr3602.

48.

Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.

Bandini S, Curcio C, Macagno M, Quaglino E, Arigoni M, Lanzardo S, Hysi A, Barutello G, Consolino L, Longo DL, Musiani P, Forni G, Iezzi M, Cavallo F.

Oncoimmunology. 2013 Sep 1;2(9):e26137. Epub 2013 Sep 12.

49.

HER-2/neu mediates oncogenic transformation via altered CREB expression and function.

Steven A, Leisz S, Massa C, Iezzi M, Lattanzio R, Lamolinara A, Bukur J, Müller A, Hiebl B, Holzhausen HJ, Seliger B.

Mol Cancer Res. 2013 Nov;11(11):1462-77. doi: 10.1158/1541-7786.MCR-13-0125. Epub 2013 Sep 11.

50.

Expression of CREB in primary pterygium and correlation with cyclin D1, ki-67, MMP7, p53, p63, Survivin and Vimentin.

Nubile M, Curcio C, Lanzini M, Calienno R, Iezzi M, Mastropasqua A, Di Nicola M, Mastropasqua L.

Ophthalmic Res. 2013;50(2):99-107. doi: 10.1159/000347124. Epub 2013 Jul 3.

PMID:
23838680

Supplemental Content

Support Center